|
ADIPOR2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.625100E-04 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
7.593200E-04 |
| Stage1-vs-Stage3 |
2.678600E-01 |
| Stage1-vs-Stage4 |
7.427800E-04 |
| Stage2-vs-Stage3 |
9.51169999999779E-05 |
| Stage2-vs-Stage4 |
9.70320000015512E-07 |
| Stage3-vs-Stage4 |
8.302000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.9258043744469E-11 |
| Normal-vs-Asian |
1.62447832963153E-12 |
| Caucasian-vs-AfricanAmerican |
7.419400E-01 |
| Caucasian-vs-Asian |
5.688000E-01 |
| AfricanAmerican-vs-Asian |
4.798000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.857000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62636570877339E-12 |
| Normal-vs-Age(81-100Yrs) |
2.4974000000233E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.213600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.002400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.674000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.704400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.907000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.922400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.74371628247627E-12 |
| Classical-VS-Follicular |
1.01719999090477E-09 |
| Classical-VS-Other |
6.279600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
1.62436730732907E-12 |
| Tall-VS-Other |
8.101800E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.639600E-02 |
| Follicular-VS-Normal |
1.52598999999531E-05 |
| Other-VS-Normal |
3.40040000046393E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.99200722162641E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.0979999949009E-08 |
|
|
